Abstract
Introduction
In 2006, the CRC market, valued at over $7 billion in the US, Europe, and
Japan, was led by the chemotherapeutic platinum agent, Sanofi-Aventis'
Eloxatin. Five existing drug classes, including the recently introduced
targeted EGFR and VEGFR inhibitors, make for a competitive market. Over the
2006-2011 forecast period, the value of the CRC market will remain relatively
stable owing to the combined effects of generic erosion, growth of existing
targeted biologics, and launch of new small-molecule targeted therapies.
Questions Answered in This Report
- - Two of the top three leading agents in CRC-Sanofi-Aventis' Eloxatin and
Pfizer' s Camptosar-will face generic erosion before 2011. The market share of
Eloxatin will fall from approximately 30% to less than 10% in 2011. How
will Sanofi-Aventis and Pfizer fare in the market following the patent expiry
of their leading brands?
- - Roche/Genentech' s VEGFR inhibitor Avastin will become the leading brand
in CRC treatment by 2011 and Bristol-Myers Squibb' s EGFR inhibitor Erbitux
will also reach blockbuster status. However, the third biologic launched in
the market, Amgen' s Vectibix, will only show modest growth. How do these
biologics differ from each other? What are physician perceptions of each? How
are the marketing companies differentiating their products?
- - Two novel small-molecule targeted therapies, AstraZeneca' s Recentin and
Pfizer' s Sutent, are expected to launch for CRC by 2011. How will the
availability of these novel oral agents alter physicians' prescribing habits?
Which emerging drug has the potential to compete with Avastin? Will other
products in development change the competitive landscape by 2011?
- - CRC is part of the broad oncology field. How does CRC fit into the
wider oncology therapeutic area of companies in the market? What strategies
are being pursued by competitors to achieve success in oncology as a whole?
Scope
- Markets Covered: United States, France, Germany, Italy, Spain,
United Kingdom, and Japan.
- Competitive Analysis: Detailed discussion of major competitors,
including Sanofi-Aventis, Roche/Genentech, Pfizer, BMS/ImClone, and Amgen; and
the emerging competitor AstraZeneca. Included is an analysis of each company' s
oncology product portfolio, strategic positioning, and development pipeline in
oncology. The report features an in-depth discussion of leading brands,
including sales and market position, SWOT analysis, and strategy initiatives.
- Physician Perception of Key Brands: Analysis of physician
perceptions of the CRC market based on a custom survey of 50 U.S.-based
oncologists. The survey is brand-focused and examines physician perceptions of
key competitors, brand attributes, messaging, and uptake of emerging agents.
- Epidemiology: Total incident and drug-treatable cases for each of
the major markets are presented in an annualized forecast from 2006 to 2011.
- Market Forecast: Annualized sales forecasts for branded agents
presented by region, drug class, molecule, and brand for 2006 to 2011,
including generic erosion and the uptake of new agents.
|
Related Report
|
View Cart
